Please login to the form below
autoimmune disease
This page shows the latest autoimmune disease news and features for those working in and with pharma, biotech and healthcare.
J&J inks $6.5bn all-cash deal to acquire Momenta
The deal will see J&J’s Janssen unit gain full access to Momenta’s portfolio of investigational autoimmune disease drugs, including anti-FcRn antibody nipocalimab, which is currently being developed ... J&J already has high stakes in the autoimmune
Latest news
-
Sanofi bolsters pipeline with $3.7bn deal for Principia Biopharma
In addition to ‘168, Sanofi gains rights to rilzabrutinib, an oral BTK inhibitor in development for the treatment of the rare autoimmune disease severe pemphigus and PRN473 Topical, a topical agent ... This acquisition strengthened the company’s
-
BMS pays $475m for Dragonfly’s IL-12 immunotherapy programme
So far, IL-12 as a target in immunotherapy has not gone beyond the hypothetical, as overproduction of IL-12 cytokines is also indicated in a number of inflammatory and autoimmune ... disease, including psoriasis and arthritis.
-
Lilly cuts deal with UK’s Sitryx for autoimmune disease drugs
At the time the biotech said it would focus on potential therapies for cancer and autoimmune conditions, with its operations supported by GSK’s drug discovery capabilities. ... Last year, Lilly announced a $650m partnership with US biotech ImmuNext in
-
FDA clears wider use for Boehringer’s Ofev in lung disease
rare autoimmune disease that affects around 100, 000 people in the US. ... The new label applies to between 18% and 32% of patients with around 200 separate disorders, including “unclassifiable ILDs, autoimmune ILDs, chronic hypersensitivity
-
Takeda buys coeliac disease partner PvP Biologics after phase 1 win
Coeliac disease is a common autoimmune condition characterised by inflammation of the small intestine, causing diarrhoea, abdominal pain and bloating, as well as impairing the ability to absorb nutrients from the ... TAK-062 is a highly targeted therapy
More from news
Approximately 5 fully matching, plus 73 partially matching documents found.
Latest Intelligence
-
30 Women Leaders in UK Healthcare (part 2)
ecosystem. In her 25-plus years in the sector, her investments have resulted in the launch of six drugs, spanning inflammatory and autoimmune disease and cancer.
-
Managing medication non-adherence
Autoimmune conditions such as Crohn’s disease can flare up through an imbalance of things like stress, lack of sleep or overworking - not just as a direct consequence of nonadherence to
-
Reaching new heights
Transformative medicine use. The overwhelming inertia in medicine use - where 97% of medicines used have been available for more than ten years - masks the contribution from transformative disease treatments, orphan drugs ... Disease treatments in 2020
-
Pharma deals during May 2014
Lumena develops oral products for treating liver disease and has two oral inhibitors of the apical sodium-dependent bile acid transporter (ASBT) in phase II to improve liver function. ... MGD010 a B-cell targeted monoclonal antibody for treatment of
-
The distressing impact of rare diseases
The report found that the economic impact of a rare disease can be truly devastating. ... A UK patient with mixed connective tissue disease (an autoimmune rare disease which has the signs and symptoms of lupus, scleroderma, polymyositis, and rheumatoid
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest appointments
-
New hires at Nanoform, Leo Pharma and Calliditas
IgA nephropathy (IgAN) – also known as Berger’s disease. ... Currently, there are no approved treatments for IgA Nephropathy, and Nefecon has the potential to be a disease-modifying treatment for patients suffering from this chronic autoimmune disease
-
Akari Therapeutics strengthens board
His expertise has seen him led transactions across a broad span of deal-types, geographies, and therapeutic disease areas and he brings experience in business and corporate development, finance, marketing and ... As Akari continues its mission to develop
-
David Horn Solomon takes the helm of Akari Therapeutics
biopharma as it focuses on the development and commercialisation of orphan autoimmune and inflammatory disease treatments.
-
Caldan Therapeutics appoints CEO
Dr Payton joins the metabolic disease specialist - a spin-out company from the Universities of Glasgow and Southern Denmark - from MAPBiotech, where he has served as chief executive officer since 2014. ... He co-founded autoimmune disease-focused Orca
-
Santhera CEO Klaus Schollmeier joins SuppreMol
In his new position at autoimmune disease specialists SuppreMol, Schollmeier succeeds Professor Peter Buckell who retires. ... He said: "The company has a very promising product candidate for the treatment of autoimmune diseases in phase II clinical
More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest from PMHub
-
PANDAS/PANS Awareness: A parent’s story
parent of a son recently diagnosed with PANDAS (paediatric autoimmune neuropsychiatric disorder associated with Streptococcus)…. ... As PANDAS is an autoimmune disease that leads to inflammation in the basal ganglia region of the brain, the symptoms
-
Innovative approaches in the treatment of multiple sclerosis
Multiple Sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system (CNS), leading to progressive and permanent disability. ... In RRMS symptoms are intermittent but relapses gradually become more frequent, severe and
-
Innovative approaches in the treatment of multiple sclerosis
Multiple Sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system (CNS), leading to progressive and permanent disability. ... In RRMS symptoms are intermittent but relapses gradually become more frequent, severe and
-
The Biosimilar Challenge
Herceptin, Avastin, Rituximab and Erbitux) and autoimmune disease (e.g. Humira, Enbrel, Remicade, MabThera and RoActemra to name a few).
-
THE OTHER SIDE OF… CROHN’S DISEASE
Meet Irene. Like millions of others worldwide (and an estimated 115, 000 in the UK), Irene suffers from Crohn’s disease, an autoimmune disorder that causes inflammation in the gut and ... She believes that they follow a “by-the-book” mentality, not
More from PMHub
Approximately 1 fully matching, plus 7 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- How will the events and exhibitions industry change post-Coronavirus?
- New study identifies drugs that are safe to use in COVID-19 treatment
- Keytruda doubles five-year survival rate in NSCLC
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
- Novacyt launches diagnostic test to differentiate between COVID-19 and flu
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
PMHub
11 London
11 London is a strategic and creative agency working in the fields of health and humanity – complex areas, but...
Latest intelligence
- Switzerland: a life sciences hub
- Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
- Responding to dynamic shifts in value communications
- OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
- Doing what we can and having fun doing it: our fundraising month
- Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...
Quick links
Infographics
